Scarica l'app Stockscreener
134.94
0.30%
0.395
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$134.54
Aprire:
$135.34
Volume 24 ore:
269.11K
Relative Volume:
0.26
Capitalizzazione di mercato:
$13.45B
Reddito:
$2.41B
Utile/perdita netta:
$305.80M
Rapporto P/E:
45.74
EPS:
2.95
Flusso di cassa netto:
$492.20M
1 W Prestazione:
-0.28%
1M Prestazione:
-6.93%
6M Prestazione:
+2.36%
1 anno Prestazione:
-7.50%
Intervallo 1D:
$133.72
$136.12
Intervallo di 1 settimana:
$129.17
$136.12
Portata 52W:
$84.23
$160.18
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Confronta NBIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
134.91 | 13.41B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
124.95 | 54.31B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.05 | 51.02B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.11B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.36 | 35.98B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
468.23 | 20.15B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-04-15 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-14 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Ripresa | Citigroup | Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Reiterato | Mizuho | Neutral |
| 2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
| 2022-06-06 | Ripresa | Jefferies | Buy |
| 2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
| 2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Iniziato | Raymond James | Outperform |
| 2020-09-30 | Iniziato | The Benchmark Company | Hold |
| 2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-09 | Iniziato | Wedbush | Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-24 | Iniziato | William Blair | Outperform |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-05 | Iniziato | Guggenheim | Neutral |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-02-06 | Reiterato | BofA/Merrill | Buy |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Aug Wrap: What hedge funds are buying Neurocrine Biosciences IncJuly 2025 Intraday Action & Verified Stock Trade Ideas - baoquankhu1.vn
Stock Market Recap: Is Neurocrine Biosciences Inc a turnaround storyQuarterly Performance Summary & Weekly Stock Performance Updates - baoquankhu1.vn
Neurocrine Biosciences chief commercial officer sells $115,940 in stock - MSN
Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 21,900 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
How Investors Are Reacting To Neurocrine Biosciences (NBIX) INGREZZA’s VMAT2 Edge Over AUSTEDO XR - simplywall.st
Neurocrine Biosciences executive sells shares worth $82,792 - MSN
A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Head To Head Clinical Data - simplywall.st
Neurocrine presents data showing INGREZZA achieved higher target occupancy - StreetInsider
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR - PR Newswire
Neurocrine Biosciences describes new GLP-1R/GIPR/GCGR agonists - BioWorld MedTech
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by SG Americas Securities LLC - MarketBeat
With Neurocrine Biosciences, Inc. (NASDAQ:NBIX) It Looks Like You'll Get What You Pay For - 富途资讯
Major Decision: Darin Lippoldt Exercises Options, Realizing $320K At Neurocrine Biosciences - Benzinga
Neurocrine Biosciences, Inc. $NBIX Shares Acquired by Nisa Investment Advisors LLC - MarketBeat
Gap Down: Can Neurocrine Biosciences Inc be recession proofBreakout Watch & Verified Momentum Watchlists - baoquankhu1.vn
Price-Driven Insight from (NBIX) for Rule-Based Strategy - Stock Traders Daily
Investor Mood: What is the Moat Score of Harbor Etf Trust Smid Capital Value EtfWeekly Trading Summary & Reliable Entry Point Alerts - baoquankhu1.vn
Neurocrine Biosciences (NASDAQ:NBIX) Given New $177.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Lobbying Update: $60,000 of NEUROCRINE BIOSCIENCES INC. lobbying was just disclosed - Quiver Quantitative
Neurocrine Biosciences CEO sells $235,577 in stock - MSN
Cerity Partners LLC Acquires 44,852 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Peregrine Capital Management LLC Reduces Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences director sells shares worth $269,167 - MSN
Reassessing Neurocrine Biosciences (NBIX) After Recent Share Price Weakness - Yahoo Finance
Is Neurocrine Biosciences (NBIX) Pricing Reflect Long Term Cash Flow Potential After Recent Weakness - simplywall.st
Neurocrine Biosciences (NBIX) Valuation Check After KINECT DCP Phase 3 Trial Failure - Sahm
How Neurocrine Biosciences Inc. stock benefits from tech adoption2025 Short Interest & Weekly Breakout Stock Alerts - Улправда
Why Neurocrine Biosciences Inc. stock could be next big winnerInsider Buying & Safe Swing Trade Setups - ulpravda.ru
Entry Recap: How Neurocrine Biosciences Inc stock benefits from tech adoptionMarket Growth Summary & Long-Term Capital Growth Strategies - moha.gov.vn
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $169.00 at Truist Financial - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Receives "Equal Weight" Rating from Morgan Stanley - MarketBeat
NBIX Analyst Downgrade by Morgan Stanley with Raised Price Targe - GuruFocus
Neurocrine Bio. stock rating downgraded by Morgan Stanley on competition - Investing.com Canada
How Neurocrine Biosciences Inc. stock performs in weak economyStock Liquidity Analysis & Affordable Growth Trading - ulpravda.ru
How Neurocrine Biosciences Inc. (NB3) stock reacts to monetary easingTechnical Analysis Insights & Crush the Market with Breakout Winners - ulpravda.ru
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Moderna (MRNA) - The Globe and Mail
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - Benzinga
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap DownHere's Why - MarketBeat
UBS lowers Neurocrine Bio. stock price target on competitive concerns By Investing.com - Investing.com Canada
Merit Financial Group LLC Boosts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
In Case You Missed It: Trial Updates, FDA Approvals & Rejections - Citeline News & Insights
Allspring Global Investments Holdings LLC Has $52.39 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Braun Stacey Associates Inc. Has $25.69 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
(NBIX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
VIRGINIA RETIREMENT SYSTEMS ET Al Boosts Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
13,364 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by Pacer Advisors Inc. - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Downgraded by Zacks Research to "Hold" - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Stock Position Lessened by Simplify Asset Management Inc. - MarketBeat
Neurocrine Biosciences executive sells shares totaling $258,263 - MSN
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neurocrine Biosciences Inc Azioni (NBIX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gano Kyle | Chief Executive Officer |
Jan 16 '26 |
Sale |
132.70 |
36,400 |
4,830,458 |
140,407 |
1.85%
0.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):